Opinion
- Author:
- Emma C. Rossi, MD
Publish date: April 20, 2022
Hormonal therapy is safe, even beneficial, for many patients with a history of gynecologic cancer, and can significantly improve their quality of l...
Opinion
- Author:
- Emma C. Rossi, MD
Publish date: March 9, 2022
Hormonal therapy has long been identified as a highly effective systemic therapy for endometrial cancers, particularly those that are low grade and...
Opinion
- Author:
- Emma C. Rossi, MD
Publish date: January 26, 2022
While pafolacianine promises to move us closer to a true “R0” (negative margins) resection of ovarian cancer, is this even a feasible goal in a dis...
Opinion
- Author:
- Emma C. Rossi, MD
Publish date: October 28, 2021
Misdiagnosis and inappropriate treatment of benign, low-level hCG levels with unnecessary chemotherapy is problematic mismanagement of gestational ...
Opinion
- Author:
- Emma C. Rossi, MD
Publish date: September 23, 2021
Arguably more important than surgical interventions, access to molecularly targeted systemic therapy is likely to bring the best outcomes for advan...
Opinion
- Author:
- Emma C. Rossi, MD
Publish date: August 24, 2021
While screening tests may not be appropriate for all patients, all patients should be asked about the early symptoms of ovarian cancer because thes...
Opinion
- Author:
- Emma C. Rossi, MD
Publish date: May 25, 2021
While both techniques are associated with equivalent efficacy in disease control, each has its virtues and advantages, and clinical judgment is nec...
Opinion
- Author:
- Emma C. Rossi, MD
Publish date: February 23, 2021
A woman with endometriosis has a two- to threefold increased risk of developing epithelial ovarian cancer, compared with nonaffected women.
Opinion
- Author:
- Emma C. Rossi, MD
Publish date: January 27, 2021
Intact removal of an ovarian cyst is a well-established gynecologic surgical principle because ovarian cancer is definitively diagnosed only in ret...
Opinion
- Author:
- Emma C. Rossi, MD
Publish date: October 28, 2020
Prospective studies are needed to determine if use of these instruments truly is safe or not.
Opinion
- Author:
- Emma C. Rossi, MD
Publish date: September 1, 2020
Tyrosine kinase receptor human epidermal growth factor receptor-2 has proven to provide an exciting target for th...
Opinion
- Author:
- Emma C. Rossi, MD
Publish date: July 28, 2020
VIN is particularly problematic because more than a quarter of patients will experience recurrence of their disease after primary therapy.
Opinion
- Author:
- Emma C. Rossi, MD
Publish date: November 1, 2019
Black women report symptoms less, have more delays in diagnosis, and experience more frequent deviations from guideline-directed diagnostics.
Opinion
- Author:
- Emma C. Rossi, MD
Publish date: August 26, 2019
Recall bias and lack of an established biologic mechanism are a few reasons perineal talc exposure isn’t considered a definitive cause of ovarian c...
Opinion
- Author:
- Emma C. Rossi, MD
Publish date: April 30, 2019
Patients who desire compounded bioidentical hormone preparations should be counseled that little is known about the safety of these preparations, c...
